mySURFACE
Surface target discovery — ImmunoEngine for cohorts
Our ImmunoEngine discovery pipeline is optimized for large cohort analyses allowing shared target discovery in cancer patient population groups. We perform custom discovery for developers of biologics, identifying and prioritizing transmembrane targets using our advanced, best-in-class prediction models. Through our expertise in whole genome target discovery, we find more, better, and novel (dark) targets, increasing the likelihood for broad population coverage.
What mySURFACE delivers
We offer large-scale patient cohort analyses with an average turnaround time of 2–3 months:
- Tumor biology fit assessment
- Glycosylation site annotation
- Antibody accessibility prediction
- Internalization capability and shedding assessment
- Surface exposure analysis
- Flexibility analysis
- Differential expression
- Coverage analysis
- myADA: next-generation Anti-Drug Antibody risk prediction
Transform protein data into actionable insights
To allow easy interpretation of complex protein data, the data is presented in a user-friendly, web-based platform specifically designed to provide a comprehensive and intuitive overview of protein characteristics and surface markers. With powerful analytics and intuitive visualization, it empowers researchers to identify and compare therapeutic targets and make data-driven decisions.
Frequently asked questions about mySURFACE
What is mySURFACE?
mySURFACE is myNEO Therapeutics’ ImmunoEngine-powered platform for surface target discovery in biologics. It identifies and prioritizes transmembrane targets from large patient cohort analyses.
Who is mySURFACE for?
mySURFACE supports developers of antibodies, bispecifics, ADCs, and cell therapies who need differentiated, high-confidence surface targets with broad population coverage.
What is the typical turnaround for mySURFACE?
Large-scale patient cohort analyses with mySURFACE have an average turnaround time of 2–3 months.
Does mySURFACE include a visualization platform?
Yes. Complex protein and surface-marker data is presented in a web-based platform designed for comparison of therapeutic targets and data-driven decisions.
Ready to use mySURFACE?
Talk to our team about integrating mySURFACE into your discovery or development workflow.